Novel Coronavirus Information Center
Elsevier’s free health and medical research on the novel coronavirus (SARS-CoV-2) and COVID-19
Welcome to Elsevier's Novel Coronavirus Information Center. Here you will find expert, curated information for the research and health community on SARS-CoV-2 (the novel coronavirus) and COVID-19 (the disease).
All resources are free to access and include guidelines for clinicians and patients.
Under the Research tab, you will find a selection of the latest early-stage and peer-reviewed research on COVID-19 from journals including The Lancet and Cell Press. We have also made more than 63k related Elsevier journal articles and book chapters free to access on ScienceDirect and PubMedCentral.
These articles are also available to download over FTP with rights for full text and data mining, re-use and analyses for as long as needed.
- Server address: coronacontent.np.elsst.com
- Protocol: sftp (SSH File Transfer Protocol)
- Username: public
- Password: beat_corona
We share daily updates to this corpus with the Allen Institute for inclusion in the multi-publisher CORD-19 dataset.
Under the Clinical information tab, you will find evidence-based skill guides and care plans for treatment, safety and patient education, along with emergency prepared resources.
In the Patient resources section, you can find our 3D4Medical coronavirus video, resources from the CDC and WHO, and information about Elsevier's Patient Access Program for research.
Margaret Trexler Hessen, MD, Director, Point of Care, Elsevier
As we enter 2021, the pandemic rages on, with much of the focus turning to vaccines. We recently added a Vaccine section to this information center, with guidance for clinicians. When we began this resource last January, we anticipated “an explosion of clinical and epidemiological information and research,” and we have certainly seen that. Our goal was to open whatever resources we could to help public health authorities, researchers and clinicians contain and manage this disease. We have provided — and continue to provide — regularly updated resources from Elsevier's content and experts. Our resources span scientific and medical journals, educational products, a clinically focused COVID-19 Healthcare Hub and periodic podcast interviews with internationally-recognized experts. There is a new R&D tool, and we have created an interactive global map of experts based on Scopus data.
We are also participating in the Education Continuity License from the Copyright Clearance Center, allowing the use of publishers’ materials in distance-learning models and other uses as required by the pandemic at no cost to the user.
In addition, Elsevier has from the beginning enabled full text and data mining of this growing body of knowledge through channels such as the NIH’s PubMed Central and the WHO database for free and without copyright limitations.
Elsevier, Cell Press and The Lancet have also joined the signatories on the Wellcome Trust’s Statement, designed to ensure that research findings and data relevant to this outbreak are shared rapidly and openly to inform the public health response and help save lives.
Elsevier has been pleased and proud to provide these resources to more than 2 million users, and we are committed to doing so as the pandemic grinds on.
If you're looking for information on our other free and low-cost access programs, including resources for patients and caregivers, you can find that here.
In this section, you can find the following resources:
- Guidelines: including new NIH and NICE guidelines; COVID-19 guidance on testing, drug therapy, ventilators, PPE, cardiovascular medicine and anesthesiology; and videos on medical procedures.
- Elsevier Clinical Solutions: Clinical Overviews on ClinicalKey, Clinical Skills for Nursing, Interprofessional Care Plans and patient engagement resources
- Mental and behavioral health: Guidance for anxiety and depression, including Patient Engagement videos
Gain access to our latest evidence-based practices and resources for COVID-19, covering topics from symptom management to diagnosis, treatment and ongoing wellness.
Expert Insights on COVID-19 with Elsevier
In Elsevier's podcast series for frontline clinicians and providers, experts share their insights into the mode of transmission and pathophysiology of the virus, how medical informatics and telemedicine are used to manage the pandemic, and best practices for emergency nursing crisis preparedness.
Listen to the podcasts
- Episode 9. SARS-CoV-2 Infection: Transmissibility, Pathophysiology and treatment features Dr. Stanley Perlman, MD, PhD, Professor of Microbiology and Immunology and Professor of Pediatrics at the University of Iowa Hospitals and Clinics. Dr. Perlman, who has studied coronaviruses for 4 decades, discusses mode of transmission of SARS-CoV-2 during asymptomatic and presymptomatic state, pathophysiology and disease progression, and touches on treatment options and vaccine development. He is interviewed by Margaret Trexler Hessen, MD, Director, Point of Care, for Elsevier.
- Episode 7: Treatment Options for COVID-19 features Jovan Borjan, PharmD, BCIDP, Clinical Pharmacy Specialist in Infectious Diseases at University of Texas MD Anderson Cancer Center, and host Dale Whitby, PharmD, Editor-in-Chief of Drug Information for Elsevier. They discuss a wide range of treatment options for COVID-19 and what we currently know based on studies. Discussion includes therapies with proposed antiviral activity, use of convalescent plasma, and agents being used to address cytokine storm. They also touch on use of anticoagulants, nutritional support, and other supportive care measures.
- Episode 6: Pulmonary Aspects of COVID-19 Disease: Clinical Course, Ventilation and Related Issues features Esther Barreiro Portela, MD, PhD, Associate Professor, Pompeu Fabra University, Hospital del Mar Respiratory Medicine Department, Hospital del Mar Medical Research Institute (IMIM), Barcelona. With host Margaret Trexler Hessen, MD, Director, Point of Care, for Elsevier, Dr. Barreiro discusses the pulmonary aspects of COVID-19, such as clinical course and pathophysiology of lung involvement, noninvasive vs. mechanical ventilation based on observed phenotypes, and myocardial dysfunction, coagulopathy and other issues relating to the pathophysiology and critical care of these patients.
- Episode 5: Biomedical Ethics During COVID-19 Pandemic, Part 2: Triaging Care, Allocation of Equipment, and Protecting the Providers features Prof. Don Postema, PhD, Program Director of Medical Ethics, HealthPartners, Center for Bioethics, University of Minnesota, and host Dr. Julibeth Lauren, PhD, APRN, ACNS-BC, VP, Editor-in-Chief, Nursing and Allied Health Practice and Patient Education at Elsevier. They discuss issues arising with patients and families, including restrictions on inpatient visiting, end-of-life issues, and how patients and families can obtain support from hospital biomedical ethics teams.
- Episode 4: Biomedical Ethics During COVID-19 Pandemic: Part 1: Supporting Patients and Families in Times of Crisis features Prof. Don Postema, PhD, Program Director of Medical Ethics, HealthPartners, Center for Bioethics, University of Minnesota, and host Dr. Julibeth Lauren, PhD, APRN, ACNS-BC, VP, Editor-in-Chief, Nursing and Allied Health Practice and Patient Education at Elsevier. They discuss issues arising with patients and families, including restrictions on inpatient visiting, end-of-life issues, and how patients and families can obtain support from hospital biomedical ethics teams.
- Episode 3: Medical Informatics and COVID-19: Role and Utility of Hospital Digital Resources and Telemedicine in Managing the Pandemic features Dr. Rebecca G. Mishuris, MD, Associate Chief Medical Information Officer at Boston Medical Center and Assistant Professor of Medicine at the Boston University School of Medicine. In this episode, Dr. Mishuris highlights the current state of EHR use to identify and track patients on the population level, advising and alerting patients, the role of telemedicine, and communication between providers and hospitals. The host is Dr. Sandy Falk, MD, Executive Editor-in-Chief, Clinical Practice Content at Elsevier.
- Episode 2: COVID-19 and Emergency Preparedness: Emergency Nursing Best Practices and Standards of Patient Care features Dr. Daniel Nadworny, DNP, RN, Director of Emergency and Patient Care Services at Beth Israel Deaconess Milton Hospital in Massachusetts. Dr. Nadworny, an expert on emergency crisis preparedness, discusses best practices and standards of care regarding isolations, triage, testing, the changing dynamic of PPE, and supporting patients, families and staff in the current crisis. The host is Dr. Julibeth Lauren, PhD, APRN, ACNS-BC, VP, Editor-in-Chief, Nursing and Allied Health Practice and Patient Education at Elsevier.
Guidelines for clinical practice, lab testing, equipment and more
- Vaccine guidelines (CDC)
- Treatment guidelines (NIH)
- COVID-19 Rapid Guidelines from NICE (via ClinicalKey)
- Guidance for healthcare professionals (CDC)
- Physiotherapy management for COVID-19 in the acute hospital setting: clinical practice recommendations, Journal of Physiotherapy (March 30, 2020). This document outlines recommendations for physiotherapy management for COVID-19 in the acute hospital setting. It includes: recommendations for physiotherapy workforce planning and preparation; a screening tool for determining requirement for physiotherapy; and recommendations for the selection of physiotherapy treatments and personal protective equipment.
Guidelines for laboratories and testing
- Information for Laboratories (CDC)
- Interim guidelines for collecting, handling and testing clinical specimens for COVID-19 (CDC)
Drug therapy guidance
- COVID-19 drug therapy — potential options. Written and continually updated by pharmacists in Elsevier's Clinical Solutions group. (Updated October 26, 2020)
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. Advice, Evidence summary (NICE, April 14, 2020)
- Possible COVID-19 Pharmacotherapies and QTc/TdP Liability, Mayo Clinic Proceedings (March 25, 2020)
- Interim guidance for COVID-19 for persons with HIV (NIH)
- Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician (Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology, March 17, 2020)
- Ventilator protocol from NIH-NHLBI ARDS Network (April 7, 2020)
- ECRI clinical evidence assessment for single ventilator use with multiple patients (April 7, 2020)
- Recommended strategies from the US Public Health Service to optimize provision of mechanical ventilation (March 30, 2020)
- Joint Statement on Multiple Patients Per Ventilator (March 26, 2020)
Use of personal protective equipment (PPE)
- Use and reuse of N95 respirators. Here is ECRI’s clinical evidence assessment on the use and reuse of N95 respirators and the ECRI COVID-19 Resource Center.
- Use of PPE by anesthesia professionals. Joint statement on use of personal protective equipment from the American Society of Anesthesiologists (ASA), Anesthesia Patient Safety Foundation (APSF), American Academy of Anesthesiologist Assistants (AAAA) and American Association of Nurse Anesthetists (AANA).
- As you work together on the front lines, the Journal of the American College of Cardiology (JACC) journals and the American College of Cardiology (ACC) are providing COVID-19 clinical guidance for global cardiovascular clinicians.
- Here you can find recently accepted manuscripts and webinars from the American College of Cardiology.
More guidance for clinicians
- Treatment guidance for lung cancer patients during the COVID-19 pandemic, Review Article, Journal of Thoracic Oncology (May 15, 2020)
- Coronavirus:guidance for anaesthesia and perioperative care providers (World Federation of Societies of Anaesthesiologists)
- Emergency preparedness resources for clinicians (CDC)
NEJM videos on clinical medicine procedures
NEJM has made a selection of procedural training videos to assist non-ICU clinical staff caring for critically ill patients. They are freely available for the during of the outbreak.
Elsevier Clinical Solutions
Guidance from ClinicalKey, Clinical Solutions Nursing, Interprofessional Practice and Patient Education
You can find more information on vaccines in Elsevier's COVID-19 Healthcare Hub Vaccine Toolkit:
Clinical Overviews on ClinicalKey are easy-to-scan clinically focused medical topic summaries designed to match the clinician workflow. Elsevier's Point-of-Care Editorial team develops them through a process that includes review and revision by a medical editor; peer reviews performed by subject matter experts; a production review to ensure consistency in style, grammar, and punctuation; and a final evaluation by the editor-in-chief.
- Multisystem inflammatory syndrome in children (MIS-C) (Updated May 17, 2021)
- COVID-19 critical care (Updated May 6, 2021)
- COVID-19 infection (Updated May 12, 2021)
Clinical Skills for Nursing
Clinical Skills for Nursing provides the highest quality evidence for nursing practice procedures for nurses to care for patients. Our Isolation Precautions and Personal Protective Equipment checklists align with CDC and OSHA guidelines:
- Skills checklist “Isolation Precautions and Personal Protective Equipment”
- Extended text: “Isolation Precautions: Personal Protective Equipment”
- Patient and family FAQ
Interprofessional Care Plans
These Interprofessional Care Plans provide an evidence-based and individualizable Interprofessional plan of care to manage fever and the possible development of pneumonia, which is consistent with the presentation of this virus. Using an interprofessional approach to patient care that aligns current evidence with the individual needs of the patient results in improved patient care outcomes.
- Care Plan Guide: Fever — Adult
- Care Plan Guide: Fever — Pediatric
- Care Plan Guide: Pneumonia — Adult
- Care Plan Guide: Pneumonia — Pediatric
Patient engagement resources
Patient engagement resources use plain language to support shared decision-making between patients and healthcare providers. The goal is to deliver the right message in the right way at the time the patient is most ready to learn. The following resources provide an overview of the novel coronavirus to help patients and their families understand their risk, identify signs and symptoms, and prevent it from spreading:
Jie-Ming Qu, Bin Cao and Rong-Chang Chen: Covid-19: The Essentials of Prevention and Treatment (Elsevier, Oct 2020)
Mental and behavioral health
With the fear and uncertainty brought on by the pandemic — and calls for social distancing — many people are experiencing increased stress, anxiety and depression. Our evidence-based patient education resources support professional practice guidelines, presenting information in a way that is easy to understand and actionable. You can find more resources in Elsevier's COVID-19 Healthcare Hub.
Elsevier has created this anxiety screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 13 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.
- Anxiety – Adults
- Anxiety: Adolescents
- Generalized Anxiety Disorder
- Generalized Anxiety Disorder Management
Interprofessional Care Planning
Book chapters and peer-reviewed articles from Elsevier journals
- Anxiety Disorders, Chapter 24, Stress: Concepts, Cognition, Emotion, and Behavior: Handbook in Stress Series, Volume 1 (Academic Press, 2016)
- Fatigue and Stress, Chapter 42, Concepts, Cognition, Emotion, and Behavior (Academic Press, 2016)
- Exercise for the Management of Anxiety and Stress-Related Disorders, Chapter 2, Exercise-Based Interventions for Mental Illness (Academic Press, 2018)
- Anxiety (Generalized Anxiety Disorder), Ferri's Clinical Advisor (Elsevier, 2020)
- Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 outbreak in China: a web-based cross-sectional, Psychiatry Research (June 2020)
- Epidemic of COVID-19 in China and associated Psychological Problems, Asian Journal of Psychiatry (June 2020)
Elsevier has created this depression screening tool as part of our COVID-19 resources for patients, clinicians and the public. It's designed for individuals age 18 years and older. For all others, please talk to your healthcare team about you or your child’s questions and concerns.
Book chapters and peer-reviewed articles from Elsevier journals
- Novac, Andrei, MD: Depressive, Bipolar, and Related Mood Disorders, Conn's Current Therapy (Elsevier, 2020 )
- Zimmerman M, D’Avanzato C: Major Depression, Ferri's Clinical Advisor (Elsevier, 2020)
- The role of social integration in the adverse effect of unemployment on mental health – Testing the causal pathway and buffering hypotheses using panel data, Social Science Research (Feb 2020)
- The psychological impact of quarantine and how to reduce it: rapid review of the evidence, The Lancet (March 2020)
- Suicidal thoughts and behaviors and social isolation: A narrative review of the literature, Journal of Affective Disorders (Feb 2019)
Related stories by Elsevier book authors
Resources from Elsevier's Clinical Solutions team in China
|Date||Title||Published by (CN)||Published by (EN)||Link|
National Microbiological Data Center;|
National Pathogen Resource Collection Center
View more resources
|Diagnosis & Treatment Guidelines 诊疗指南|
|4月16日||新冠肺炎疫情社区防控与服务工作精准化精细化指导方案||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202004/7838c406600d4d38a11f5675c98a2ecf.shtml|
|4月14日||大专院校新冠肺炎疫情防控技术方案||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202004/7838c406600d4d38a11f5675c98a2ecf.shtml|
|4月13日||Guidelines for Investigation and Management of Close Contacts of COVID-19 Cases||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/aa16e57b-d717-40f0-bf34-265c6e011508|
|4月13日||Technical Guidelines for COVID-19 Laboratory Testing||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/0f6dc581-08f4-4828-97f0-9cc805969bbb|
|Chinese Center for Disease Control and Prevention||Guidelines for Personal Protection of Specific Groups from COVID-19||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/65577621-f02e-4c47-b883-f70659c300b3|
|4月13日||Technical Guidelines for Disinfection of Special Sites for COVID-19||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/7120f4f9-e03d-4164-9bf2-3e097d4b3734|
|4月11日||Protocol for the Management of Asymptomatic Persons Infected with COVID-19 Virus||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/18987f85-feb8-44c8-b94e-8bdcd8ad141a|
|4月8日||新冠病毒无症状感染者管理规范||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202004/9d3edaaebb9a4c369f42c61039be35fe.shtml|
|4月8日||新冠肺炎出院患者复诊复检工作方案（试行）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202004/1ba91504225040a7ac2c9eda48cc4e7e.shtml|
|4月1日||新型冠状病毒肺炎重型、危重型病例诊疗方案（试行 第二版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202004/c083f2b0e7eb4036a59be419374ea89a.shtml|
|3月29日||Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7)||国家卫生健康委员会||National Health Commission||http://en.nhc.gov.cn/2020-03/29/c_78469.htm|
|3月19日||Guidelines for COVID-19 Epidemiological Investigations||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/99b0a945-a516-410a-9260-7db46e792877|
|3月15日||Guidelines for Investigation and Management of Close Contacts of COVID-19 Cases||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/aa16e57b-d717-40f0-bf34-265c6e011508|
|3月13日||Technical Guidelines for COVID-19 Laboratory Testing||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/0f6dc581-08f4-4828-97f0-9cc805969bbb|
|3月13日||Guidelines for Personal Protection of Specific Groups from COVID-19||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/65577621-f02e-4c47-b883-f70659c300b3|
|3月13日||Technical Guidelines for Disinfection of Special Sites for COVID-19||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/7120f4f9-e03d-4164-9bf2-3e097d4b3734|
|3月13日||新冠肺炎出院患者健康管理方案（试行）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202003/056b2ce9e13142e6a70ec08ef970f1e8.shtml|
|3月12日||重症新型冠状病毒肺炎管理专家推荐意见||中华医学会||Chinese Medical Association||https://www.cma.org.cn/art/2020/3/12/art_2928_33535.html|
|3月12日||北京协和医院麻醉科手术室新冠肺炎（COVID-19）疫情期间区域分级防护规范（试行）||中华医学会||Chinese Medical Association||https://www.cma.org.cn/art/2020/3/12/art_2928_33535.html|
|3月11日||Protocol for Prevention and Control of COVID-19 (Edition 6)||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/e97a6f76-c07f-4d43-bd73-51067a4fc9f9|
|3月7日||新型冠状病毒肺炎防控方案（第六版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202003/4856d5b0458141fa9f376853224d41d7.shtml|
|3月4日||新型冠状病毒肺炎诊疗方案（试行第七版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml|
|2月26日||新型冠状病毒肺炎（NCP）床旁超声心动图检查及远程超声诊断实施方案（第一版）||中华医学会||Chinese Medical Association||https://www.cma.org.cn/art/2020/2/26/art_2928_33048.html|
|2月24日||新型冠状病毒肺炎重型、危重型病例诊疗方案（试行第二版）||中华医学会||Chinese Medical Association||https://www.cma.org.cn/art/2020/2/24/art_2928_32959.html|
|2月21日||新型冠状病毒肺炎防控方案（第五版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202002/a5d6f7b8c48c451c87dba14889b30147.shtml|
|2月19日||新型冠状病毒肺炎诊疗方案（试行第六版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202002/8334a8326dd94d329df351d7da8aefc2.shtml|
|2月17日||新型冠状病毒肺炎疫情防控期间养老机构老年人就医指南||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202002/c26a0ca4a58d47489c5781493b2ac624.shtml|
|2月14日||新型冠状病毒感染相关ICD代码||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202002/dcf3333b740f4fabad5f9f908d1fc5b4.shtml|
|2月8日||新型冠状病毒肺炎诊疗方案（试行第五版 修正版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml|
|2月7日||新型冠状病毒感染的肺炎防控方案（第四版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202002/573340613ab243b3a7f61df260551dd4.shtml|
|2月5日||新型冠状病毒感染的肺炎诊疗方案（试行第五版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml|
|2月1日||新型冠状病毒感染的肺炎患者遗体处置工作指引（试行）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/yzygj/s7659/202002/163c26a24057489dbf64dba359c59a5f.shtml|
|1月28日||新型冠状病毒感染的肺炎防控方案（第三版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202001/470b128513fe46f086d79667db9f76a5.shtml|
|1月28日||新型冠状病毒感染的肺炎病例转运工作方案（试行）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202001/ccee6ec0942a42a18df8e5ce6329b6f5.shtml|
|1月27日||新型冠状病毒感染的肺炎诊疗方案（试行第四版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202001/4294563ed35b43209b31739bd0785e67.shtml|
|1月25日||关于“新型冠状病毒感染的肺炎”诊疗建议方案（V2.0）||中国医学科学院北京协和医院||Peking Union Medical College Hospital, CAMS||https://new.qq.com/omn/HLH20200/HLH2020012501009300.html|
|1月24日||《新型冠状病毒肺炎诊疗快速指南》||华中科技大学同济医学院附属同济医院专家组||Tongji Hospital, Tongji Medical College of HUST||https://xw.qq.com/health/20200124010910/HLH2020012401091000|
|1月24日||《武汉协和医院处置2019新型冠状病毒感染策略及说明》||华中科技大学同济医学院附属协和医院专家组||Xiehe Hospital, Tongji Medical College of HUST||https://www.dxy.cn/bbs/newweb/pc/post/42662254|
|1月23日||湖北省新型冠状病毒感染的肺炎诊疗方案(试行第一版）||湖北省医疗救治专家组||Medical Expert Panel of Hubei Province||https://xw.qq.com/cmsid/20200123A0KNOW00|
|1月23日||医疗机构内新型冠状病毒感染预防与控制技术指南（第一版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202001/b91fdab7c304431eb082d67847d27e14.shtml|
|1月23日||新型冠状病毒实验室生物安全指南（第二版）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202001/0909555408d842a58828611dde2e6a26.shtml|
|1月22日||新型冠状病毒感染的肺炎诊疗方案（试行第三版）（PDF可下载）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml|
|Epidemic situation 疫情分布|
|Daily update||新型冠状病毒感染的肺炎疫情分布||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://2019ncov.chinacdc.cn/2019-nCoV/|
|Research articles 研究进展和经典图书|
|4月30日||Nursing Management in General Hospitals during the Prevention and Control of COVID-19||北京大学医学出版社||Peking University Medical Press||http://cdn.pumpedu.com.cn/pdfview/index.php?cc=21650en|
|4月30日||Handbook of Common Nursing Technology for COVID-19||北京大学医学出版社||Peking University Medical Press||http://cdn.pumpedu.com.cn/pdfview/index.php?cc=21667en|
|4月30日||Specialty Issues in the Management and Treatment of COVID-19||北京大学医学出版社||Peking University Medical Press||http://cdn.pumpedu.com.cn/pdfview/index.php?cc=21634en|
|4月19日||Handbook of Basic Epidemiological Knowledge on Coronavirus Disease 2019(COVID-19)-110 Questions & Answers||北京大学医学出版社||Peking University Medical Press||https://mp.weixin.qq.com/s/FCegqoxc5X72uqdsulzc1A|
|4月19日||《新型冠状病毒肺炎流行病学知识110问》||北京大学医学出版社||Peking University Medical Press||https://mp.weixin.qq.com/s/zkPzfFLuPDdymj0od4eUHw|
|4月2日||COVID-19 Academic Research Communication Platform (English) - Free to read||中华医学会杂志社||CMA Publishing House||http://medjournals.cn/COVID-19/index.do|
|4月2日||新型冠状病毒肺炎科研成果学术交流平台（中文）- 免费阅读||中华医学会杂志社||CMA Publishing House||http://medjournals.cn/2019NCP/index.do|
|2月28日||COVID-19影像表现及研究进展||中华医学会放射学分会青年委员会||Youth Committee, Radiology Branch of Chinese Medical Association||https://mp.weixin.qq.com/s/MnJyIzobbDQdicAQScG1ow|
|2月18日||A strategy to prevent future epidemics similar to the 2019-nCoV outbreak||Biosafety and Health||Biosafety and Health||https://www.sciencedirect.com/science/article/pii/S2590053620300161|
|2月18日||Technical guidance for laboratory testing of 2019-nCoV infection (third edition)||Biosafety and Health||Biosafety and Health||https://www.sciencedirect.com/science/article/pii/S2590053620300136|
|2月18日||Laboratory biosafety guide for the novel coronavirus||Biosafety and Health||Biosafety and Health|
|1月25日||中国新型冠状病毒感染病例首批临床数据报告（解读, with link to sourse articles）||The Lancet Weichat Official Account||The Lancet Weichat Official Account|
|1月22日||Notes from the Field: An Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province...[2020-01-22]||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/e3c63ca9-dedb-4fb6-9c1c-d057adb77b57|
|1月21日||A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019-2020[2020-01-21]||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/a3907201-f64f-4154-a19e-4253b453d10c|
|1月21日||引自《默里及纳达尔呼吸医学》，V Courtney Broaddus 主编，李为民、程德云主译，人民卫生出版社，2018||李为民、程德云主译，人民卫生出版社，2018||Elsevier, with content quoted from translation published by PMPH||Influenza|
|Patient Education 患者教育|
|2020.1.24||轻症疑似2019新型冠状病毒患者及密切接触人员如何进行自我管理||北京协和医院呼吸科||Respiratory Department, Peking Union Medical College Hospital, CAMS||http://m.sohu.com/a/368777653_102327|
In this section, you can find the following resources:
- Journal articles, including coronavirus hubs by The Lancet and Cell Press
- Early-stage research (preprints on SSRN)
- Infographic: global research trends in infectious disease
- Interactive map: global disease outbreak experts
Related articles freely available on ScienceDirect
Elsevier has made coronavirus-related articles and book chapters freely available for as long as is necessary, commencing in February 2020. This content is now freely available on ScienceDirect and PubMedCentral
On this Coronavirus Resource Hub, curated by members of the Cell Press editorial team, you'll find content about the outbreak as it appears in Cell Press journals along with our policies for submitting papers.
1science, acquired by Elsevier in 2018, was created to expand the scope of existing abstracting and analytics databases. It includes quality controlled academic and research documents in all disciplines and languages, from all countries. Its core index, 1findr, currently comprises more than 120 million metadata records, including over 30 million links to free full-text articles selected from about 100,000 referred scholarly journals. The Coronavirus Research Repository is a custom extraction from 1findr comprising articles on COVID-19, MERS, SARS and coronaviruses in general.
This French version of our Novel Coronavirus Information Center includes regular updates on research in French journals.
Call for papers
Various Elsevier journals have special issues related to COVID-19
- MethodsX special issue on Pandemics and their impacts on global economic and financial systems. This special issue will focus on descriptions of methods for economics and finance researchers that can be used to study not only COVID-19 but any pandemic for that matter.
- The Journal of Molecular Diagnostics seeks manuscripts related to SARS-CoV-2. The Journal of Molecular Diagnostics — the official journal of the Association for Molecular Pathology (AMP) — is calling for manuscripts that display new or improved molecular methods which may be applied to diagnosis or monitoring of SARS-CoV-2. Accepted manuscripts will be expedited through the publication process as much as possible and will be free through Elsevier’s Novel Coronavirus Information Center and ScienceDirect. Please refer to the guide for authors for information on submission.
- American Journal of Pathology seeks manuscripts related to SARS-CoV-2. The American Journal of Pathology — the official journal of the American Society for Investigative Pathology — is calling for manuscripts that address mechanisms of SARS-CoV-2 pathogenesis or provide a foundation for future mechanistic inquiries. Accepted manuscripts will be expedited through the publication process as much as possible and will be free to access through Elsevier’s Novel Coronavirus Information Center and ScienceDirect. Please refer to the guide for authors for information on submission.
- Medical Mycology Case Reports special Issue: COVID-19 associated pulmonary aspergillosis (CAPA). The high number of personal observations shared by clinicians who have been taking care of patients with invasive pulmonary aspergillosis as a complication of severe COVID-19 disease and first reports indicating that up to 30 percent of those patients have signs of Aspergillus co-infections is alarming.This special issue aims to bring together clinical experience in the management of patients with CAPA presented as individual case reports or small case series.
- Chaos, Solitons & Fractals Special Issue: Modeling and forecasting of epidemic spreading: the case of Covid-19 and beyond. The editors write: "[There] is a pressing and immediate need for the scientific community to come together and provide novel and better methods, strategies, forecasting techniques and models to understand and mitigate the effects of this and future pandemics. ..."
- Mathematical Biosciences Virtual Special Issue: Transmission dynamics and control of Novel Coronavirus SARS-CoV-2. This virtual issue welcomes contributions on the use of mathematical, statistical and computational modeling approaches for providing deeper mechanistic insights into the transmission dynamics and control of SARS-CoV-2.
- Open-source journal HardwareX calls for COVID-19 equipment designs. Papers will be free to publish and free to read.
Content hubs from other publishers
Elsevier is among various publishers who are making relevant papers freely available. Others include: Springer Nature | Wiley | NEJM | BMJ | American Society for Microbiology | American College of Cardiology| Chongqing VIP Information. Many publishers have also signed the Wellcome Trust Statement committing to share relevant nCoV research and data rapidly and openly.
You can find all these publishers and more on LitCovid — the National Library of Medicine's curated hub of scientific literature about novel coronavirus. It currently provides access to more than 3,200 articles in PubMed and is being updated daily.
Early-stage research: preprints on SSRN
Rapidly evolving healthcare emergencies necessitate the quick dissemination of research. The growing role of preprints, or early-stage research, was acknowledged in the Ebola and Zika virus outbreaks as a way of “accelerating the dissemination of scientific findings to support responses to infectious disease outbreaks.” SSRN , Elsevier’s platform for the rapid worldwide dissemination of early-stage research, is committed to making authors' coronavirus related research available immediately. Research on SSRN is free to download and upload. It is important to note that these papers have not benefited from the pivotal role of the peer-review process, which validates and improves the quality of final published journal articles.
Top 10 SSRN downloads of the week*
- Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study 9,063
- Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1 7,435
- Effects of BNT162b2 mRNA Vaccination on COVID-19 Disease, Hospitalisation and Mortality in Nursing Homes and Healthcare Workers: A Prospective Cohort Study Including 28,594 Nursing Home Residents, 26,238 Nursing Home Staff, and 61,951 Healthcare Workers in Catalonia 432
- Recommendations for the Recognition, Diagnosis, and Management of Patients with Post COVID-19 Condition ('Long COVID'): A Delphi Study 367
- Decreased Infectivity Following BNT162b2 Vaccination 144
- Myopia Progression in Children During COVID-19 Home Confinement in Argentina 114
- 6-Month Follow Up of Hospitalised COVID-19 Patients: A Nationwide Cohort Study of 8679 Patients in Germany 80
- Behavioral Nudges Increase COVID-19 Vaccinations: Two Randomized Controlled Trials 74
- Safety, Tolerability and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Healthy Children and Adolescents: A Randomised, Double-Blind, and Placebo-Controlled, Phase 1/2 Clinical Trial 52
- Vaccine Effectiveness of the First Dose of ChAdox1 nCOV-19 and BNT162b2 Against SARS-CoV-2 Infection in Residents of Long Term Care Facilities (VIVALDI Study) 28
* Calculated on Thursday, April 15, 2021
Infographic: Global research trends
Download Elsevier’s infographic on infectious disease research trends, top research orgs and the impact of outbreaks
Interactive map: global coronavirus experts
This map represents the most active institutions researching COVID-19 and related coronaviruses. We ran a search in Scopus — a source-neutral abstract and citation database of over 75 million records — for publications related to COVID-19, coronaviruses and related diseases such as SARS and MERS. We then used the resulting ~96,000 publications to identify the currently active researchers and institutions that are working in these areas, the map shows the most prolific global institutions and links to their authors. (Updated: April 10, 2021)
Click on a pin to see more about the institution, the numbers of researchers and their publications that matched our query in Scopus. Then link through to the researcher's profiles in Scopus to learn more about their areas of expertise.
Vaccines and drug discovery
Webinar: Demystifying COVID-19 Vaccines
Join John McConnell, Editor-in-Chief of The Lancet Infectious Diseases, and Ylann Schemm, Director of the Elsevier Foundation and Corporate Responsibility at Elsevier, in a conversation about how COVID-19 vaccines work and their safety and efficacy in preventing infection. John will share insights into the public's most frequently asked questions. Join us for an invaluable opportunity to secure answers to your own pressing questions.
Wednesday, April 28, 2021 10am EDT | 2pm GMT | 4pm CET
- Clinical Overviews
- Nursing Skills
- Patient Education
- Patient Education videos
- CDC Resources
- Vaccines Blog
You can find these and more resources on Elsevier's COVID-19 Healthcare Hub Vaccine Toolkit
A new clinical preprint (not yet peer-reviewed) posted on SSRN highlights the immunogenicity and efficacy of the Oxford/AstraZeneca vaccine as well as the potential for a substantial reduction in transmission. This study has been covered by various news outlets, including the BBC | BBC Health | CNN | Bloomberg | Financial Times
You can search for vaccine studies in our Research section.
R&D tool to capture clinical trial data is free for researchers studying COVID-19
Elsevier recently launched Veridata Electronic Data Capture (EDC), which enables clinical researchers to capture clinical trial data in a secure environment. To assist researchers working to develop vaccines and other therapies for COVID-19, Elsevier has pledged to make Veridata EDC available for free. Interested clinical researchers can contact Elsevier customer support via e-mail at email@example.com and apply for a demo account. Following the necessary compliance training, they will receive a free 12-month license. Read the press release
Gender and COVID-19 Group on Mendeley
This collection of research, studies and other references covers the sex and gender dimensions of the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. The library is a public group, free for anyone in the world to join, access and add. References - articles, preprints, news articles, blog posts, magazine articles, reports, etc - include those compiled by Dr. Rosemary Morgan at Johns Hopkins University and colleagues from the Gender and COVID-19 Working Group, as well as those from other compilations and sources. The library on the Mendeley platform includes >500 references related to Gender and COVID-19, as well as gender and other infectious disease/epidemics, which you can locate and find resources, include direct citations and references within your work, and add additional references & folders directly to the group. We invite the community to continue posting new references as they’re published/become available even if also being added to an existing compilation elsewhere.
COVID-19 drug therapy — updated on October 26
Pharmacists in Elsevier's Clinical Solutions group write about potential treatment options for COVID-19. Read their paper.
Drug information from Elsevier's R&D Solutions
Elsevier's R&D solutions for pharma and life sciences integrate data, analytics and technology to help researchers make data-driven drug discovery and development decisions and streamline literature monitoring for pharmacovigilance. Here, we use those tools to generate information relevant to combating COVID-19:
- 121 drugs and natural products successfully used against previous coronavirus infections including SARS. This list was generated using Elsevier's Pathway Studio.
- 393 substances that interact with 25 targets related to 6 target species including SARS coronavirus, Middle East respiratory syndrome coronavirus, human Middle East respiratory syndrome coronavirus, Human coronavirus 229E, Coronaviridae and Coronavirinae, with normalized affinity value > 6. This list was generated using Elsevier’s Reaxys Medicinal Chemistry.
- Autophagy is a cellular recycling process, whereby cells eliminate damaged or diseased components in order to regenerate and build new healthier cells; thus, viruses are usually identified and disposed of in this way. Would it be possible to induce the autophagy process and limit the viral infection by using some substances? Pathway Studio provides a list of 406 compounds that have been reported inhibiting autophagy pathway, and their related references as well as a list of 802 compounds that have activating roles in autophagy.
Mayo Clinic Proceedings: Possible COVID-19 Pharmacotherapies and QTc/TdP Liability
The Mayo Clinic Proceedings journal has released a pre-proof of a new paper titled Possible COVID-19 Pharmacotherapies and QTc/TdP Liability. From the abstract: "As the COVID-19 global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the “off label” re-purposing of drugs such as hydroxychloroquine and lopinavir/ritonavir with the potential for unwanted QT interval prolongation, and a risk of drug induced sudden cardiac death. With the possibility that a significant proportion of the world’s population could receive soon COVID-19 pharmacotherapies with torsadogenic potential for therapy or post-exposure prophylaxis, this document serves to help healthcare providers mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk to personnel of COVID 19 exposure and conserving the limited supply of personal protective equipment. Read the paper
Pure portal: Discover research collaborators and institutions globally
Use this Pure portal to discover novel coronavirus related research collaborators and institutions around the world. It uses Elsevier’s Natural Language Fingerprinting technology, scientific taxonomies and Scopus profiles and can be used to filter and find associated publications.
Here, you will find guidance and commentary from experts along with official guidance from major health organizations such as the CDC and WHO. For research on public health and related topics, see our Research section.
COVID-19 treatments exemplify the significance of public-private sector R&D but haven't received the same attention as vaccines, creating possible knowledge gaps. This free Research!America webinar — Science v Covid-19: Promising Treatments Explained (recorded on Feb 25, 2021) — features expert panelists including Dr Rajesh T. Gandhi Infectious Diseases Society of America; Dr James L. Madara, CEO and EVP American Medical Association (AMA); Denise Brooks-Williams, Senior VP and CEO North Market, Henry Ford Health System; Dr Michael Ybarra, MD, VP and Chief of Medical Affairs, PhRMA. Register to view on demand
Free on demand: 14th Vaccine Congress Online Edition
Elsevier's 14th Vaccine Congress – Online Edition: Combatting the threat of Covid-19, held in September 2020, featured leading experts in vaccinology sharing their knowledge on the current developments and challenges we face. Sessions are available free on demand. Register here
Dr. Fauci features Cell paper in Congressional hearing
“This is work we really need to pursue,” Dr. Fauci says, touting findings that T cells from common coronaviruses may offer protection against COVID-19
Studies to improve face masks and disinfect the air
- In a new article in Materials Today Physics, researchers describe their air disinfection system to control the spread of COVID-19, for which they filed a provisional patent application: Catching and killing of airborne SARS-CoV-2 to control spread of COVID-19 by a heated air disinfection system (July 7, 2020)
- In Open Ceramics, researchers describe a sputtered antimicrobial/virucidal silver nanoclusters/silica composite coating to significantly improve the protection capacity of face masks while also being suitable for coating air filters and other surfaces: Virucidal effect against Coronavirus SARS-CoV-2 of a silver nanocluster/silica composite sputtered coating (June 6, 2020)
This special issue in the Journal of Aerosol Science, from 2018, has articles that are relevant to COVID-19.
COVID-19 Pandemic Collection in AJPM
View this collection in the American Journal of Preventive Medicine
Articles in this COVID-19 Pandemic collection cover pressing public health issues, including vulnerable populations at risk and economic impact:
View the articles
- Relationships Between Initial COVID-19 Risk Perceptions and Protective Health Behaviors: A National Survey
- Preventing COVID-19 and its Sequela: “There Is No Magic Bullet ... It's Just Behaviors”
- Clinical Characteristics, Associated Factors, and Predicting COVID-19 Mortality Risk: A Retrospective Study in Wuhan, China
- COVID-19 and the Correctional Environment: The American Prison as a Focal Point for Public Health
- Vulnerable Populations: Weathering the Pandemic Storm
- Disparities in the Population at Risk of Severe Illness From COVID-19 by Race/Ethnicity and Income
- Mandatory Social Distancing Associated With Increased Doubling Time: An Example Using Hyperlocal Data
By combining their data and analytics with those of other industry stakeholders, LexisNexis Health Care created a COVID-19 dataset and interactive visualization to provide insights on at-risk populations and care capacity risks. View the map
Progress in Disaster Science: COVID-19 Special Collection
Keeping wider disciplinary involvement in mind, the journal Progress in Disaster Science plans to publish special issues as a major learning from the evolving nature of the pandemic. Papers on the following topics related to COVID-19 response are encouraged: public health response, governance and policy analysis, emerging technologies, roles of civil societies and other stakeholders, citizen participation, collateral hazards, business continuity, recovery planning, economic/fiscal implications. Read the special collection
Journal of Aerosol Science: Special section on "Virus Aerosol Science, Sampling, and Control"
The editor, Prof. Chris Hogan, writes: "The Journal of Aerosol Science has long been a resource on understanding viruses in aerosols, methods to sample airborne viruses, and to control and inactivate airborne viruses. In this collection, we highlight numerous studies over the past decade focusing on virus aerosol science. In addition, we invite authors to contribute this virtual collection by submitting to this journal, selecting the option: "SARS-CoV-2 & Virus Aerosols." Read the special section
COVID-19 podcasts and webinars by CIDRAP
Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here
More public health resources
- CDC vaccine guidance
- Disaster Epidemiology and Surveillance, Chapter 27, Jekel's Epidemiology, Biostatistics, Preventive Medicine, and Public Health, 5th Edition (Elsevier, 2020)
- Impacts on Society and Economy (OECD)
- Interactive map showing global spread of COVID-19 (WHO)
- Interactive map shows global spread of the virus (Johns Hopkins CSSE)
- Guidance for businesses and employers (CDC)
- Travel precautions (CDC)
- Information and updates (CDC)
- Novel coronavirus advice for the public (WHO)
- Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance (WHO)
- National Genomic Data Center (China) 2019 nCoV Resource Center (新型冠状病毒信息库)
Official coronavirus guidance from various countries:
- Sources of updated information in the EU/EEA countries
- Panamerican Health Organization (Latin American branch of the WHO)
عدوى فيروس كورونا المستجد (patient education in Arabic)
Elsevier's Patient Access Program for research
With our Patient Access Program, patients and their caregivers can receive medical or healthcare related research papers by emailing firstname.lastname@example.org. This email is constantly monitored by our support teams, who aim to provide individual articles at no cost to patients and caregivers within 24 hours. Requesters simply need to include the article title and authors, date published, and/or the DOI or URL if available so we can locate the article as quickly as possible. Learn more
COVID-19 podcasts and webinars
Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here
Since January 2020, Elsevier has created an online resource center with free information in English and Mandarin on the novel coronavirus (COVID-19).
This Novel Coronavirus Information Center is hosted on Elsevier Connect, the company’s public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource center — including this research content — immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource center remains active.